Medable is to combine its end-to-end software platform with Vault Health’s capabilities in diagnostics, logistics and remote care services for decentralised trials.

The alliance between the two firms is based on the companies’ commitment to offering clinical trials to patients through remote monitoring and high-touch services.

This move will aid in making trials broad and accessible and eventually aiding new drugs to be launched in the market rapidly.

Under the partnership, the firms will offer a unified experience for patients, trial sites and sponsors by integrating Medable’s software-as-a-service (SaaS) platform and Vault’s tech-enabled operational expertise.

Sponsors will be able to effortlessly provide Vault home healthcare visits and TeleVisits, home testing and diagnostics, virtual site expertise and associated logistics, planning and status monitoring through Medable’s apps for patients and sites.

Medable CEO and co-founder Dr Michelle Longmire said: “The future of clinical research is decentralised, whether that’s in a traditional clinic, a virtual site, a local pharmacy or someone’s home.

“Teaming up with Vault Health allows us to make clinical trial participation much more convenient for patients, providing them with easy testing and diagnostic options, as well as expert remote care they can access from anywhere.”

Vault is claimed to offer the first at-home PCR test, authorised by the US Food and Drug Administration, to the market and has supplied more than ten million Covid-19 tests.

Medable’s SaaS platform has been used in over 150 decentralised and hybrid trials in 60 countries.

This March, Medable partnered with Seqster to combine real-world patient data streams in a decentralised trials platform.